liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
A Randomized, Cross-Over Study in Patients with Neuroendocrine Tumors (NETs) to Assess Patient Preference of Lanreotide Autogel Given by either Self/Partner or Healthcare Professional in NEUROENDOCRINOLOGY, vol 94, issue , pp 29-29
Sahlgrens University Hospital.
Odense University Hospital.
Karolinska University Hospital.
St Olav Hospital.
Show others and affiliations
2011 (English)In: NEUROENDOCRINOLOGY, Karger , 2011, Vol. 94, 703-710 p.Conference paper (Refereed)
Abstract [en]

Background: Lanreotide Autogel® is supplied in prefilled syringes. Therefore, it is possible for patients with neuroendocrine tumors to use self-/partner-administered injections. The primary objective of this study was to assess the proportion of patients preferring self/partner injections over injections administered by health care professionals, and to describe the impact of self/partner administration on efficacy, safety, and costs. Methods: Of 62 eligible patients, 26 (42%) patients with neuroendocrine tumors treated with a stable dose of lanreotide Autogel 90 mg or 120 mg every 4 weeks agreed to participate in this Phase IV, international, open-label, crossover study, conducted at hospitals in Sweden, Norway, and Denmark. Patients were randomized to two blocks, starting with administration of lanreotide Autogel by either self/partner or a health care professional. Preference for injections administered by self/partner or health care professionals was measured, as well as efficacy, safety, and health care resource utilization (both direct and indirect costs). Results: Of 25 evaluable patients, 22 (88%) preferred self/partner injections, mainly because they experienced increased independence. Based on all patients asked to participate (n = 62), 35% preferred self/partner injections on a regular basis. There was no difference in efficacy or safety between the two administration blocks. Conclusion: Many patients with neuroendocrine tumors prefer self/partner injection of lanreotide Autogel, and are able to self/partner inject without any impact on efficacy or safety. This administration method seems to provide a good alternative for suitable patients to increase patient independence and reduce the number of clinic visits.

Place, publisher, year, edition, pages
Karger , 2011. Vol. 94, 703-710 p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-73363DOI: 10.2147/PPA.S34337ISI: 000297638900093OAI: diva2:471323
Available from: 2012-01-02 Created: 2012-01-02 Last updated: 2014-10-24

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Wall, Najme
By organisation
OncologyFaculty of Health SciencesDepartment of Oncology
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 38 hits
ReferencesLink to record
Permanent link

Direct link